Evidence map›Paper›PMID 36608129›Full record

ArticleScience advances2023

Exposure to isocyanates predicts atopic dermatitis prevalence and disrupts therapeutic pathways in commensal bacteria.

Jordan Zeldin, Prem Prashant Chaudhary, Jacquelyn Spathies, Manoj Yadav, Brandon N D'Souza, Mohammadali E Alishahedani, Portia Gough, Jobel Matriz, Andrew J Ghio, Yue Li and 4 more

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06096857 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial of Cardamom and Topical Roseomonas in Atopic Dermatitis

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2024 to 2027Enrolled120ConditionsAtopic Dermatitis, EczemaArmsRoseomonas mucosa (RSM2015) and Cardamom seeds, Placebo (sucrose)
NCT07271381 narecruitingnot on this mapstarted 2026, after this paper: background citation

THREAT: Testing Harms Related to Exposure to Allergenic and Epithelial Toxins

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2026 to 2031Enrolled120ConditionsAllergic, InflammatoryArmsEnvironmental Exposures, Control Exposures
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Interpretable Machine Learning for Survival Analysis.Biometrical journal. Biometrische Zeitschrift · 2025
    Review
  12. Skin and gut microbiome in atopic dermatitis: Mechanisms and therapeutic opportunities.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025
    Review
  13. Targeting Pollutants in the Treatment and Prevention of Atopic Dermatitis.Immunology and allergy clinics of North America · 2025
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Challenges and Future Trends in Atopic Dermatitis.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Jordan ZeldinEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3259-1381
Prem Prashant ChaudharyEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3467-8608
Jacquelyn SpathiesEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-7731-1363
Manoj YadavEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Brandon N D'SouzaEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3507-0362
Mohammadali E AlishahedaniEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Portia GoughEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-0201-7597
Jobel MatrizEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.
Andrew J GhioU.S. Environmental Protection Agency, Chapel Hill, NC, USA.ORCID 0000-0003-0502-6448
Yue LiDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD, USA.ORCID 0000-0002-1874-2999
Ashleigh A SunEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5648-0723
Lawrence F EichenfieldDepartments of Dermatology and Pediatrics, University of California San Diego, La Jolla, CA, USA.ORCID 0000-0002-2760-0474
Eric L SimpsonDepartment of Dermatology, Oregon Health and Science University, Portland, OR, USA.ORCID 0000-0003-0853-0252
Ian A MylesEpithelial Therapeutics Unit, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9316-3703
National Institutes of Health · USEnvironmental Protection Agency · USOregon Health & Science University · USUniversity of California San Diego · USUniversity of Maryland, College Park · US

Funding

Host Immunity Against BacteriaZIAAI001043 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MYLES, IAN · 2009 to 2025
$18.9M
6 · The paper itself

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin condition increasing in industrial nations at a pace that suggests environmental drivers. We hypothesize that the dysbiosis associated with AD may signal microbial adaptations to modern pollutants. Having previously modeled the benefits of health-associated

Indexed as

Dermatitis, AtopicBacteriaDysbiosisHumansIsocyanatesPrevalenceSkinIsocyanates

Identifiers

PMID36608129
PMCPMC9821876
OpenAlexW4313706731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.